Abstract
Recent studies have identified that the EGFR T790M mutation is responsible for acquired resistance to EGFR inhibitors in up to 50% of cases and that NSCLC strains that display wild-type EGFR exhibit sensitivity to EGFR inhibitors dependent on the degree to which they have been subjected to EMT. In contrast, EGFR inhibitor-resistant NSCLC strains with mesenchymal phenotype showed decreased…